Pharm2Farm reported on Thursday the availability of the Pro-Larva mask that integrates the unique British technology based on copper nanoparticles to create an effective virucidal barrier against Covid-19 and other types of viruses, including the flu virus.
The company added that the Pro-Larva mask is the new antiviral mask that kills 99.9% of Covid-19 in the first five minutes of contact. The new revolutionary device, unlike the traditional masks, offers an unsurpassed level of protection against viruses, not only for those around the wearer but also for the wearer.
According to the company, the Pro-Larva mask is designed for hospitals, retirement homes, schools, retail and leisure sectors.
A spin out from Nottingham Trent University, Pharm2Farm Ltd produces and sells these masks through an exclusive license from NTU.
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Oticon launches Oticon Zeal, a discreet, fully featured in-the-ear hearing aid
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
OSR Holdings to acquire Korean non-invasive glucose monitor developer Woori IO
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux